Non-communicable diseases are a serious global problem for humanity. Metabolic syndrome, cardiovascular disease, type 2 diabetes, obesity, and their complications lead to increased mortality and reduce quality of patients’ life. Non-alcoholic fatty liver disease (NAFLD) is currently recognized as one of the most common causes of chronic liver disease worldwide. Current scientific evidence suggests that there is a close relationship between the gut microbiota and chronic pathologies. The results of studies have established the existence of cause and effect relations between impaired microbiocenosis of the intestine, imbalance of the immune system, as well as in one of the key pathogenetic roles in the development and progression of NAFLD, pancreatic steatosis, increasing intestinal permeability, reducing the protective properties of mucosa, enhancing translocation of microorganisms into the systemic circulation. As no conventional approaches to the diagnosis and treatment of patients with NAFLD and metabolic syndrome have been developed at present, the therapy of such patients should be directed, first of all, to factors that contribute to their development and progression. Considering the latest research findings, the role of gut microbiota in the pathogenesis of metabolic syndrome is justified. The use of techniques affecting this correlation is substantiated. A promising method of treating such diseases is the prescription of pre- and probiotics to modify the gut microbiota.
This article analyzes the case of a patient with NAFLD, pancreatic steatosis, who used a therapy that had an effect on the patient’s microbiota. The article contains system analysis, bibliosemantics, and case analysis of a specific patient. The sources were obtained from the scientific and statistical database of medical information. This clinical case highlights the relevance of this problem in medical practice and the feasibility of further research in this field. The impact of microbiome on human body is significant, and correcting disorders can reduce the risk of associated diseases. Therefore, preventing and correcting early-stage pathologies will reduce mortality rate and improve patients’ quality of life.
2. Aron-Wisnewsky J., Vigliotti C., Witjes J., Le P., Holleboom A. G., Verheij J., Nieuwdorp M., Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat. Rev. Gastroenterol. Hepatol. 2020. Vol. 17, No 5. P. 279–297.
3. Campo L., Eiseler S., Apfel T., Pyrsopoulos N. Fatty liver disease and gut microbiota: a comprehensive update. Journal of Clinical and Translational Hepatology. 2019. Vol. 7, No 1. P. 56–60.
4. Gensollen T., Iyer S. S., Kasper D. L., Blumberg R. S. How colonization by microbiota in early life shapes the immune system. Science. 2016. Vol. 352 (6285). P. 539–544.
5. Jasirwan C. O. M., Lesmana C. R. A., Hasan I., Sulaiman A. S., Gani R. A. The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms. Bioscience of Microbiota, Food and Health. 2019. Vol. 38, No 3. P. 81–88.
6. Linares D. M., Ross P., Stanton C. Beneficial microbes: the pharmacy in the gut. Bioengineered. 2016. Vol. 7. P. 11–20.
7. Liu Q., Liu S., Chen L., Zhao Z., Du S., Dong Q., Xin Y., Xuan S. Role and effective therapeutic target of gut microbiota in NAFLD/NASH. Experimental and Therapeutic Medicine. 2019. Vol. 18, No 3. P. 1935–1944.
8. Zhu L., Baker R., Baker S. Gut microbiome and nonalcoholic fatty liver diseases. Pediatr. Res. 2015. Vol. 77. P. 245–251.